EUVIMEDEUVIMED entdecken
Crossref

Development of Nuclear In-Situ Sequencing (NIS-Seq)

Caroline I. Fandrey

bonndoc (University of Bonn) · 11.09.2025

DOI: 10.48565/bonndoc-651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift bonndoc (University of Bonn), erschienen am 11.09.2025. Verfasst von Caroline I. Fandrey.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR perturbation screening can globally identify genes that are required for a biological process to function. As conventional perturbation screening methods rely on FACS- or growth-based enrichment of cells with a phenotype of interest, they are limited to a small subset of relevant phenotypes for which a cell population can be enriched. Optical perturbation screening, in contrast, expands accessible phenotypes to any phenomenon which can be observed by light microscopy. However, as it relies on the cellular transcription machinery to identify CRISPR perturbations by coloured spots, it is limited to a small subset of transcriptionally active and large cell types. To overcome this limitation, we have developed Nuclear In Situ Sequencing (NIS-Seq), which uses a chimeric U6/T7 promoter cassette to enable in vitro transcription of a CRISPR sgRNA cassette directly from genomic DNA. The IVT product is then used as a template to generate bright coloured sequencing spots inside each cell’s nucleus. NIS-Seq enables screening of any nucleated cell type at high density and high library complexity, extending CRISPR screening to a wide range of biological processes. We validate the versatility of NIS-Seq by applying it to eight cell types from two species, including primary human macrophages. In addition, we demonstrate the detection of library matching barcodes in lentivirally transduced human skin tissue. The efficacy of the method is further demonstrated by four genome-wide optical screens in living cells, where we identify key players in inflammation-related cellular pathways. In addition, a targeted end-to-end validation screen was performed to investigate inflammasome activation in primary human macrophages. Notably, arrayed RNP validation confirmed ANTXR2-dependent but NLRC4-independent inflammasome activation, suggesting an unknown activation mechanism in primary human macrophages, distinct from known mechanisms in THP1 cell lines. Finally, we demonstrated how NIS-Seq can be used to analyse the spatial arrangement of genetic loci within the nucleus, quantifying the distances of multiple genomic loci from the nuclear envelope across a pool of cells. The results support current models that suggest a defined radial localisation of specific genetic loci within the nucleus, while the distances between individual loci are mostly random. NIS-Seq significantly expands the scope of optical pooled screening to a multitude of cell types, tissues, and phenotypes, offering new opportunities for the identification of disease-relevant proteins and potential drug targets. In addition, this novel technology opens up exciting possibilities for mapping the nuclear architecture at scale, which may deepen our understanding of spatial genome regulation.

Schlagwörter

in vitro transcriptionsingle guide RNAhuman macrophagesinflammasome activationANTXR2NLRC4spatial genome organizationnuclear organizationskininflammation

Zitieren

APA

Fandrey, C. I. (2025). Development of Nuclear In-Situ Sequencing (NIS-Seq). bonndoc (University of Bonn). https://doi.org/10.48565/bonndoc-651

Vancouver

Fandrey CI. Development of Nuclear In-Situ Sequencing (NIS-Seq). bonndoc (University of Bonn). 2025. doi:10.48565/bonndoc-651

BibTeX
@article{Fandrey2025,
  author = {Fandrey, Caroline I.},
  title = {Development of Nuclear In-Situ Sequencing (NIS-Seq)},
  journal = {bonndoc (University of Bonn)},
  year = {2025},
  doi = {10.48565/bonndoc-651}
}
Kostenlos starten →